{
    "nctId": "NCT00322374",
    "briefTitle": "Phase I Combination w/ Epirubicin",
    "officialTitle": "A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Number of Participants With a Dose Limiting Toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \u226518 years\n* Histologically or cytologically confirmed diagnosis of metastatic breast cancer\n* Measurable or nonmeasurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST)\n\nExclusion Criteria:\n\n* Number of prior chemotherapy lines of treatment in the metastatic setting \u22652",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}